HomeSARTF • OTCMKTS
add
Sartorius AG
Previous close
$195.24
Year range
$193.23 - $313.00
Market cap
14.76B EUR
Avg Volume
1.00
P/E ratio
-
Dividend yield
-
Primary exchange
ETR
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 793.60M | -2.11% |
Operating expense | 276.90M | 5.45% |
Net income | 14.20M | -4.70% |
Net profit margin | 1.79 | -2.72% |
Earnings per share | 0.87 | -17.92% |
EBITDA | 169.60M | -6.56% |
Effective tax rate | 26.95% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 579.20M | 97.07% |
Total assets | 9.79B | -1.67% |
Total liabilities | 6.02B | -16.62% |
Total equity | 3.78B | — |
Shares outstanding | — | — |
Price to book | — | — |
Return on assets | 1.73% | — |
Return on capital | 2.04% | — |
Cash Flow
Net change in cash
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 14.20M | -4.70% |
Cash from operations | 266.10M | 47.92% |
Cash from investing | -93.50M | 96.05% |
Cash from financing | -186.20M | -108.01% |
Net change in cash | -12.00M | -109.11% |
Free cash flow | 111.86M | 1,064.33% |
About
Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest stock market index. As a leading partner to the biopharmaceutical research and industry, Sartorius supports its customers in the development and production of biotech drugs and vaccines - from the initial idea in the laboratory to commercial production. Sartorius conducts its operating business in the two divisions Bioprocess Solutions and Lab Products&Services. The divisions bundle their respective businesses according to the same application areas and customer groups. The divisions share some of the infrastructure and central services. Wikipedia
Founded
1870
Website
Employees
13,762
